ライフサイエンスコーパス: National Committee

1 onal Committee Report, and 2014 Eighth Joint National Committee.

2 classified with 5 categories from the Joint National Committee 7 with a sixth category added to dist

3 ated 3 populations (usual care, Eighth Joint National Committee based, SPRINT based) using nationally

4 e greater for SPRINT-based than Eighth Joint National Committee-based treatment.

5 tional Committee Report or 2014 Eighth Joint National Committee BP goals but could also lead to more

6 us fungi was assessed in comparison with the National Committee for Clinical Laboratory Standards (NC

7 The National Committee for Clinical Laboratory Standards (NC

8 ents against the results generated using the National Committee for Clinical Laboratory Standards (NC

9 nd by six independent laboratories using the National Committee for Clinical Laboratory Standards (NC

10 icrodilution test performed according to the National Committee for Clinical Laboratory Standards (NC

11 National Committee for Clinical Laboratory Standards (NC

12 using the microdilution format assay of the National Committee for Clinical Laboratory Standards (NC

13 Several modifications to the National Committee for Clinical Laboratory Standards (NC

14 treonam as resistant as suggested by current National Committee for Clinical Laboratory Standards (NC

15 s by a microdilution method adopted from the National Committee for Clinical Laboratory Standards (NC

16 and broth) and procedures recommended by the National Committee for Clinical Laboratory Standards (NC

17 ken to determine the accuracy of the current National Committee for Clinical Laboratory Standards (NC

18 402 yeast isolates was assessed against the National Committee for Clinical Laboratory Standards (NC

19 ollowing a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NC

20 SabDex) with fluconazole was compared to the National Committee for Clinical Laboratory Standards (NC

21 se (YNB) broth microdilution method with the National Committee for Clinical Laboratory Standards (NC

22 rding to a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NC

23 lysed horse blood, similar in concept to the National Committee for Clinical Laboratory Standards (NC

24 ared in four different laboratories with the National Committee for Clinical Laboratory Standards (NC

25 antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards (NC

26 tance according to current guidelines of the National Committee for Clinical Laboratory Standards (NC

27 The National Committee for Clinical Laboratory Standards (NC

28 ermediate, or resistant according to current National Committee for Clinical Laboratory Standards (NC

29 ndida with fluconazole was compared with the National Committee for Clinical Laboratory Standards (NC

30 x separate laboratories tested replicates of National Committee for Clinical Laboratory Standards (NC

31 istant strains were determined by use of the National Committee for Clinical Laboratory Standards (NC

32 d was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NC

33 The National Committee for Clinical Laboratory Standards (NC

34 in B and fluconazole susceptibilities by the National Committee for Clinical Laboratory Standards (NC

35 red in three different laboratories with the National Committee for Clinical Laboratory Standards (NC

36 National Committee for Clinical Laboratory Standards (NC

37 ida spp. was assessed in comparison with the National Committee for Clinical Laboratory Standards (NC

38 voriconazole were compared with that of the National Committee for Clinical Laboratory Standards (NC

39 lus spp. was assessed in comparison with the National Committee for Clinical Laboratory Standards (NC

40 tococcus neoformans was assessed against the National Committee for Clinical Laboratory Standards (NC

41 e selected 131 E. coli isolates that met the National Committee for Clinical Laboratory Standards (NC

42 d according to procedures established by the National Committee for Clinical Laboratory Standards (NC

43 veterinary methods recently developed by the National Committee for Clinical Laboratory Standards (NC

44 ates) to nine antimicrobial agents using the National Committee for Clinical Laboratory Standards (NC

45 tes of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NC

46 The National Committee for Clinical Laboratory Standards (NC

47 tes of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NC

48 In 1999, the National Committee for Clinical Laboratory Standards (NC

49 andida spp. was assessed against that of the National Committee for Clinical Laboratory Standards (NC

50 ested by broth microdilution against various National Committee for Clinical Laboratory Standards (NC

51 ared with visual determination of MIC by the National Committee for Clinical Laboratory Standards (NC

52 eloped by the Antifungal Subcommittee of the National Committee for Clinical Laboratory Standards (NC

53 conducted according to the guidelines of the National Committee for Clinical Laboratory Standards and

54 by the standard broth macrodilution method (National Committee for Clinical Laboratory Standards app

55 more appropriate breakpoint than the current National Committee for Clinical Laboratory Standards bre

56 " of growth during susceptibility testing by National Committee for Clinical Laboratory Standards bro

57 ole, and ravuconazole were determined by the National Committee for Clinical Laboratory Standards bro

58 MICs were determined according to a National Committee for Clinical Laboratory Standards bro

59 performed according to the guidelines of the National Committee for Clinical Laboratory Standards by

60 SBL)-producing isolates testing resistant by National Committee for Clinical Laboratory Standards cri

61 MB agar plates were prepared as described in National Committee for Clinical Laboratory Standards doc

62 Methods recommended by the National Committee for Clinical Laboratory Standards for

63 y according to procedures established by the National Committee for Clinical Laboratory Standards for

64 termined for 10 clinical isolates, following National Committee for Clinical Laboratory Standards gui

65 e and gram-negative strains that fulfill the National Committee for Clinical Laboratory Standards gui

66 m/ml susceptible category defined by current National Committee for Clinical Laboratory Standards gui

67 Adapting the National Committee for Clinical Laboratory Standards M27

68 elated well with the results obtained by the National Committee for Clinical Laboratory Standards M27

69 igational triazole voriconazole by using the National Committee for Clinical Laboratory Standards M27

70 bility testing method, the recently released National Committee for Clinical Laboratory Standards M27

71 B were tested by using a modification of the National Committee for Clinical Laboratory Standards M27

72 TCC 6258) were tested in accordance with the National Committee for Clinical Laboratory Standards M27

73 rent sites and compared this method with the National Committee for Clinical Laboratory Standards M27

74 Center 1 used the National Committee for Clinical Laboratory Standards M27

75 Testing was performed in accordance with the National Committee for Clinical Laboratory Standards M27

76 olved upon repeat testing were tested by the National Committee for Clinical Laboratory Standards M7-

77 Antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards mac

78 concentrations (MICs) were determined by the National Committee for Clinical Laboratory Standards met

79 ic susceptibilities of P. acnes by using the National Committee for Clinical Laboratory Standards met

80 e detection of mecA by PCR with detection by National Committee for Clinical Laboratory Standards met

81 ricin B, and 5-fluorocytosine (5FC) by using National Committee for Clinical Laboratory Standards mic

82 f fluconazole was determined by the standard National Committee for Clinical Laboratory Standards pro

83 ere compared to the results generated by the National Committee for Clinical Laboratory Standards ref

84 ility testing method with the results of the National Committee for Clinical Laboratory Standards ref

85 MIC determinations were made by the National Committee for Clinical Laboratory Standards ref

86 The National Committee for Clinical Laboratory Standards sta

87 erence macrodilution method developed by the National Committee for Clinical Laboratory Standards Sub

88 sistance according to the definitions of the National Committee for Clinical Laboratory Standards wer

89 the M. marinum strains tested (MIC90, at the National Committee for Clinical Laboratory Standards) br

90 boratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) br

91 tive criteria and QC limits (accepted by the National Committee for Clinical Laboratory Standards) sh

92 Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards).

93 Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards).

94 By using the interpretive guidelines of the National Committee for Clinical Laboratory Standards, 26

95 susceptibility has been standardized by the National Committee for Clinical Laboratory Standards, an

96 boratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards, or

97 rmed according to the recommendations of the National Committee for Clinical Laboratory Standards, wa

98 ults compared to the time to availability of National Committee for Clinical Laboratory Standards-rec

99 ed by the standard method recommended by the National Committee for Clinical Laboratory Standards.

100 st value within the range recommended by the National Committee for Clinical Laboratory Standards.

101 tentative broth macrodilution method of the National Committee for Clinical Laboratory Standards.

102 and microdilution methods recommended by the National Committee for Clinical Laboratory Standards.

103 was determined by methods recommended by the National Committee for Clinical Laboratory Standards.

104 by the reference agar dilution method of the National Committee for Clinical Laboratory Standards.

105 microdilution method, as recommended by the National Committee for Clinical Laboratory Standards.

106 ntial advantages over the M27-A assay of the National Committee for Clinical Laboratory Standards.

107 is study is recommended for inclusion in the National Committee for Laboratory Standards method for t

108 In 1996, the National Committee for Quality Assurance (NCQA) commissi

109 However, the National Committee for Quality Assurance (NCQA) is imple

110 health insurance plans participating in the National Committee for Quality Assurance (NCQA) quality

111 ent-centered medical home recognition by the National Committee for Quality Assurance (NCQA).

112 s) participating in the HEDIS program of the National Committee for Quality Assurance during 1999, an

113 ns that reported quality-of-care data to the National Committee for Quality Assurance for 2002 and 20

114 st (level 3) medical-home recognition by the National Committee for Quality Assurance, a designation

115 atients cared for by providers practicing in National Committee for Quality Assurance-recognized pati

116 atients cared for by providers practicing in National Committee for Quality Assurance-recognized pati

117 Level III PCMH, as defined by the National Committee for Quality Assurance.

118 Joint National Committee goal blood pressure for all adults wa

119 Report goals, or achieving 2014 Eighth Joint National Committee goals could prevent 3.0 million (UR,

120 eport goals, and achieving 2014 Eighth Joint National Committee goals, respectively.

121 on patterns closely followed the Sixth Joint National Committee guideline recommendations.

122 panel members appointed to the Eighth Joint National Committee (JNC 8)" disqualified nearly 98% of p

123 panel members appointed to the Eighth Joint National Committee (JNC 8)" has generated considerable c

124 panel members appointed to the Eighth Joint National Committee (JNC 8; 2014 BP guideline) proposed l

125 published in the Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evalu

126 Since 2003, the Seventh Report of the Joint National Committee (JNC-7) has been the predominant guid

127 eatment at visit 2 based on the Eighth Joint National Committee (JNC-8) hypertension guidelines const

128 The Eighth Joint National Committee (JNC-8) recommended treating systolic

129 tudy was to examine the association of Joint National Committee (JNC-V) blood pressure and National C

130 The sixth Joint National Committee (JNC-VI) classification system of blo

131 lationships to the sixth report of the Joint National Committee (JNC-VI) on Prevention, Detection Eva

132 compared to the seventh report of the Joint National Committee (JNC7).

133 cted in agreement with the guidelines of the National Committee of Ethic Reflection on Animal Experim

134 The fifth report of the Joint National Committee on Detection, Evaluation, and Treatme

135 eatment and management guidelines, the Joint National Committee on Detection, Evaluation, and Treatme

136 ssure control rates (using the Seventh Joint National Committee on hypertension targets) achieved ove

137 are preparing the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation

138 uideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

139 The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation,

140 ve again been recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation,

141 uideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

142 Compared with the 2003 Seventh Joint National Committee on Prevention, Detection, Evaluation,

143 and (3) stage of hypertension based on Joint National Committee on Prevention, Detection, Evaluation,

144 criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

145 ideline and under the previous seventh Joint National Committee on Prevention, Detection, Evaluation,

146 according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

147 criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

148 n the basis of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,

149 e status was "normal" according to the Joint National Committee on Prevention, Detection, Evaluation,

150 erns with recommendations of the Sixth Joint National Committee on Prevention, Detection, Evaluation,

151 gh normal" per the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,

152 ry (defined by the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,

153 d-pressure category (as defined by the Joint National Committee on Prevention, Detection, Evaluation,

154 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

155 uidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,

156 "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,

157 sage by larger HMOs and by those with higher National Committee on Quality Assurance (NCQA) ratings.

158 The National Committee on Quality Assurance has determined t

159 The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluat

160 ased link to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluat

161 rtension" in the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluat

162 P goals, and (3) achieving 2014 Eighth Joint National Committee panel member report BP goals.

163 The 2014 Eighth Joint National Committee panel recommendations for management

164 The 2014 Eighth Joint National Committee panel recommended a therapeutic targe

165 of 2 BP treatments based on the Eighth Joint National Committee recommendations and SPRINT (Systolic

166 BP levels, (2) achieving 2003 Seventh Joint National Committee Report BP goals, and (3) achieving 20

167 re (BP) levels, achieving 2003 Seventh Joint National Committee Report goals, and achieving 2014 Eigh

168 rent BP levels, achieving 2003 Seventh Joint National Committee Report goals, or achieving 2014 Eight

169 CVD events than achieving 2003 Seventh Joint National Committee Report or 2014 Eighth Joint National

170 e 2017 ACC/AHA guideline, 2003 Seventh Joint National Committee Report, and 2014 Eighth Joint Nationa

171 cal Care Medicine has representatives on the national committees that focus on code creation and defi

172 panel members appointed to the Eighth Joint National Committee titled "2014 Evidence-Based Guideline

173 cording to the established definition (Joint National Committee VII and European Society of Hypertens